The role of leukocytes in disseminated intravascular coagulation associated with sepsis

Sepsis

Volumn 3, Issue 2, 1999, Pages 135-142

  Okajima, Kenji ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GABEXATE MESILATE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOCYTE ELASTASE; NAFAMSTAT MESILATE; OXYGEN RADICAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DAMAGE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ACTIVITY; ENDOTHELIUM CELL; FIBRINOLYSIS; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ADHERENCE; MONOCYTE; MULTIPLE ORGAN FAILURE; NEUTROPHIL; SEPSIS; THROMBOGENESIS;

EID: 0033503238     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009899400421     Document Type: Article

References (79)

1. Levi M, ten Cate H, van der Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975-979.
2. Corrigan JJ, Jordan CM. Heparin therapy in septicemia with disseminated intravascular coagulation. New Engl J Med 1970;283:778-782.
3. Thomas L, Good RA. Studies on the generalized Shwartzman reaction. I. General observation concerning the phenomenon. J Exp Med 1952;96:605-624.
4. Okajima K, Wang YP, Okabe H, Inoue M, Takatsuki K. Role of leukocytes in the activation of intravascular coagulation in patients with septicemia. Am J Hematol 1991;36:265-271.
5. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990;70:427-451.
6. Stephans KE, Ishizaka A, Wu ZH, Larrick JW, Raffin A. Granulocyte depletion prevents tumor necrosis factor mediated acute lung injury in guinea pigs. Am Rev Respir Dis 1988;138:1300-1307.
7. Taylor FB, Chang ACK, Peer GT, Mather T, Blick K, Catlett R, Lockhart CMS, Esmon CT. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991;78:364-368.
8. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats. Thromb Res 1995;78:117-125.
9. Naworth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163:740-745.
10. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989;73:159-165.
11. Kobayashi M, Shimada K, Ozawa T. Human recombinant interleukin-1ζ and tumor necrosis factor-α -mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990;144:383-390.
12. Schleef RR, Bevilacua MP, Sawdey M, Gimborne MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. J Biol Chem 1988;263:5797-5803.
13. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989;74:165-172.
14. Wada H, Tamaki S, Tanigawa M, Takagi M, Mori Y, Deguchi A, Katayama N, Yamamoto T, Deguchi K, Shirakawa S. Plasma level of IL-1β in disseminated intravascular coagulation. Thromb Haemost 1991;65:364-368.
15. Marks JD, Marks CB, Luce JM, Montogomery AB, Turner J, Metz CA, Murray JF. Plasma tumor necrosis factor in patients with septic shock. Am Rev Respir Dis 1990;141: 94-97.
16. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-777.
17. Newman W, Beal LD, Carson CW, Hunder GG, Graben N, Randhawa ZI, Gopal TV, Wiener-Kronish J, Matthay MA. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. J Immunol 1993;150:644-654.
18. Okajima K, Uchiba M, Murakami K, Okabe H, Takatsuki K. Plasma levels of soluble E-selectin in patients with disseminated intravascular coagulation Am J Hematol 1997;54: 219-224.
19. Adams DO, Hamilton TA. The cell biology of macrophage activation. Annu Rev Immunol 1985;2:283-318.
20. Van der Poll, Levi M, Hack CE, ten Cate H, van Deventer SJH, Eerenberg AJM, de Groot ER, Jansen J, Gallati H, Büller HR, ten Cate JW, Aarden LA. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994;179: 1253-1259.
21. Heremans H, Dillen C, Put W, Van Damme J, Billiau A. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur J Immunol 1992;22:2395-2401.
22. Stouthard JML, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996;76:738-742.
23. Niessen RWL, Lamping RJ, Jansen PM, Prins MH, Peters M, Taylor Jr. FB, de Vijlder JJM, ten Cate JW, Hack CE, Sturk A. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and baboons. Thromb Haemost 1997;78:1088-1092.
24. Schipper HG, Roos J, van de Meulen F, ten Cate JW. Antithrombin III deficiency in surgical intensive care patients. Thromb Res 1981;21:73-80.
25. Starkey PM. Elastase and cathepsin G. the serine proteinase of human neutrophil leukocytes and spleen. In: Barret AJ, ed. Protreinase in Mammalian Cells and Tissues. Amsterdam: Elsevier/North-Holland Biomedical Press, 1977:57-59.
26. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Finkel BS, Palladino MR. Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol 1985;135:2069-2073.
27. Jochum M, Lamber N, Heimburger N, Fritz H. Effect of human granulocyte elastase on isolated human antithrombin III. Hoppe-Seylers Zeitschrift für Physiologische Chemie 1981;362:103-112.
28. Abe H, Okajima K, Okabe H, Takatsuki K, Binder BR. Granulocyte proteases and hydrogen peroxide synergistically inactive thrombomodulin of endothelial cells in vitro. J Lab Clin Med 1994;123:874-881.
29. Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. J Clin Invest 1993;91:1721-1730.
30. Kushimoto S, Okajima K, Okabe H, Binder BR. Role of granulocyte elastase in the formation of hemorrhagic shock-induced gastric mucosal lesions in the rat. Crit Care Med 1996;24:1041-1046.
31. Tateson JE, Moncada S, Vane JR. Effects of prostacyclin on cyclic AMP concentration in human platelets. Prostaglandins 1977;13:389-397.
32. Crutchley DJ, Conanan LB, Toledo AW, Solomon DE, Que BG. Effects of prostacyclin analogues on human endothelial cell tissue factor expression. Arterioscl Throm Vas 1993;13:1082-1089.
33. Kainoh M, Maruyama I, Nishio S, Nakadate T. Enhancement by beraprost sodium, a stable analogue of prostacyclin, in thrombomodulin expression on membrane surface of cultured vascular endothelial cells via increase in cyclic AMP level. Biochem Pharmacol 1991;41:1135-1140.
34. Yoshikawa T, Murakami M, Furukawa Y, Kondo M. Effects of prostaglandin 12 and thromboxane A2 synthtase inhibitor on endotoxin-induced disseminated intravascular coagulation in rats. J Clin Biochem Nutr 1986;1:31-37.
35. LeRoy EC, Ager A, Gordon JL. Effects of neutrophil elastase and other proteases on porcine aortic endothelial prostacyclin production, adenine nucleotide release, and responses to vasoactive agents. J Clin Invest 1984;74:1003-1010.
36. Suttop N, Nolte A, Wilke A, Drenckhaln D. Human neutrophil elastase increases permeability of cultured pulmonary endothelial cell monolayer. Int J Microcirculation 1993;13: 187-203.
37. Okajima K, Fujise R, Motosato Y, Ushijima M, Okabe H, Takatsuki K. Plasma levels of granulocyte elastase-a1-proteinase inhibitor complex in patients with disseminated intravascular coagulation: Pathophysiologic implications. Am J Hematol 1994;47:82-88.
38. Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, Chang RJ, Lin JH, Vilander L, Andrews WH, Light DR. Oxidation of a specific methionine in thrombomodulin by activated neutrophil productsblocks cofactor activity. J Clin Invest 1992;90:2565-2573.
39. Shasby DM, Yorec M, Shasby SS. Exogenous oxidants initiates hydrolysis of endothelial cell inositol phospholipids. Blood 1988;72:491-499.
40. Muller-Berghaus G, Schneberger R. Hageman factor activation in the generalized Shwartzman reaction induced by endotoxin. Br J Haematol 1971;21:513-527.
41. Carvalho AC, Demarins S, Scott CF, Silver LD, Schmaier AH, Colman RW. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 1988;112:270-277.
42. Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M, Cohen AB, Colman RW. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983;72:1672-1677.
43. Wachtfogel YT, Pixely RA, Kucich U, Abrams W, Weinbaum G, Schapira M, Colman RW. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986;67:1731-1737.
44. Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FB Jr, Colman RW. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal antibody to block contact activation in baboolns. J Clin Invest 1993;91:61-68.
45. Uchiba M, Okajima K, Murakami K, Okabe H, Okamoto S, Okada T. Effects of plasma kallikrein specific inhibitor and active-site blocked factor VIIa on the pulmonary vascular injury induced by endotoxin in rats. Thromb Haemost 1997;78:1209-1214.
46. Jansen PM, Pixley RA, Brouwer M, de Jong JW, Chang AC, Hack CE, Taylor FB Jr, Colman RW. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996;87:2337-2344.
47. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989;163: 1404-1411.
48. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effect of antithrombin III (AT III) and Trp49-modified AT III on plasma levels of 6-keto-PGF1a in rats. Thromb Res 1995;80:201-208.
49. Eisenhut T, Sinha B, Grottrup-Wolfers E, Semmler J, Siess W, Endres S. Prostacyclin analog suppress the synthesis of tumor necrosis factor in LPS-stimulated human perpheral blood mononuclear cells. Immunopharmacology 1993;26: 259-264.
50. Kainoh M, Iai R, Umetsu T, Hattori M, Nishio S. Prostacyclin and beraprost sodium as seppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 1990;39:477-484.
51. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1992;270: L921-L930.
52. Uchiba M, Okajima K, Murakami K. Effects of various doses of antithrombin III on endotoxin-induced endothelial cell injury and coagulation abnormalities in rats. Thromb Res 1998;89:233-241.
53. Uchiba M, Okajima K. Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: Novel biological activity of AT III. Semin Thromb Hemost 1997;23:581-588.
54. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III - New therapeutic implications. Semin Thromb Hemost 1998;24:27-32.
55. Okajima K. Antithrombin prevents endotoxin-induced pulmonary vascular injury by inhibiting leukocyte activation. Blood Coagul Fibrinol 1998;9(Suppl 2):S25-S37.
56. Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982;257:859-864.
57. Suzuki K, Stenflo J, Dahlback B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1993;258:1914-1920.
58. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997;272:L197-L202.
59. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87:642-647.
60. Uchiba M, Okajima K, Murakami K, Nawa H, Okabe H, Takatsuki K. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemostas 1995;74: 1265-1270.
61. Uchiba M, Okajima K, Murakami K, Johno M, Okabe H, Takatsuki K. Recombinant thrombomodulin prevents endotoxin-induced lung injury by inhibiting activation of leukocytes in rats. Am J Physiol 1996;271:L470-L475.
62. Uchiba M, Okajima K, Murakami K, Johno M, Mohri M, Okabe H, Takatsuki K. Recombinant thrombomodulin prevents the endotoxin-induced increase in pulmonary vascular permeability through protein C activation. Am J Physiol 1997;273:L889-L894.
63. Girard TJ, Warren LA, Novotony WF, Likert K, Brown SG. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989;338:518-520.
64. Carr C, Bild GS, Chang AC, Peer GT, Palmier MO, Frazier RB, Gustafson ME, Wun T-C, Creasy AA, Hinshaw LB, Taylor FB Jr, Galluppi GR. Recombinant E-coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1995;44:126-137.
65. Taylor FB Jr, Chang ACK, Peer G, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD 100 Escherichia coli. Blood 1998;91:1609-1615.
66. Isobe H, Okajima K, Murakami K, Harada N. Antithrombin prevents endotoxin-induced hypotension in rats by inhibiting induction of nitric oxide synthetase. Crit Care Med 1999;27(Suppl):A46.
67. Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999;93:157-164.
68. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrate in septic shock with disseminated intravascular coagulation. Chest 1992;104:882-888.
69. Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Sem Hematol 1995;32(Suppl 2):19.
70. Taylor Jr FB, Chang A, Esmon CT, D'Angelo A, Vigano-D, Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-925.
71. Okajima K, Imamura H, Koga S, Inoue M, Takatsuki K, Aoki N. Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol 1990;33:277-278.
72. Taenaka N, Shimada Y, Hirata T. Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis. Crit Care Med 1983;9:735-738.
73. Takahashi H, Takizawa S, Tatewaki W, Nagai K, Wada K, Hamano M, Shibata A. Nafamostat mesilate (FUT-175) in the treatment of patients with disseminated intravascular coagulation. Thromb Haemost 1989;62:372.
74. Murakami K, Okajima K, Uchiba M, Okabe H, Takatsuki K. Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Crit Care Med 1996;24:1047-1053.
75. Taoka Y, Okajima K, Uchiba M, Murakami K, Kushimoto S, Johno M, Naruo M, Okabe H, Takatsuki K. Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats. Crit Care Med 1997;25:874-879.
76. Harada N, Okajima K, Kushimoto S. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation. Crit Care Med 1999;27:1958-1964.
77. Uchiba M, Okajima K, Abe H, Okabe H, Takatsuki K. Effect of nafamostat mesilate on the activity of extrinsic pathway of coagulation. Thromb Res 1994;74:155-161.
78. Okajima K, Uchiba M, Murakami K. Nafamostat mesilate. Cardiovasc Drug Rev 1995;13:51-65.
79. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats. Am J Resp Crit Care Med 1997;155:711-718.